Lifileucel: the first cellular therapy approved for solid tumours.

Autor:	Julve M; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK. Electronic address: Maximilian.julve@nhs.net., Lythgoe MP; Department of Surgery and Cancer, Imperial College London, Du Cane Road, W12 0HS, London, UK., Larkin J; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK., Furness AJS; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Jazyk:	angličtina
Zdroj:	Trends in cancer [Trends Cancer] 2024 Jun; Vol. 10 (6), pp. 475-477. Date of Electronic Publication: 2024 May 09.
DOI:	10.1016/j.trecan.2024.04.003
Abstrakt:	The US Food and Drug Administration (FDA) approval of lifileucel, for advanced melanoma, represents the first cellular therapy to reach the clinic for solid cancers. Here, we summarise this landmark approval, consider the associated regulatory pathway, and evaluate the challenges that remain to ensure effective implementation of this advanced 'living' therapy. Competing Interests: Declaration of interests M.P.L. and M.J. declare no conflicts of interest. J.L. declares the following: honorariums (Eisai, Novartis, Incyte, Merck, touchIME, touchEXPERTS, Pfizer, Royal College of Physicians, Cambridge Healthcare Research, Royal College of General Practitioners, VJOncology, Agence Unik, BMS, Immatics, Insighter, and GCO); consultancies (iOnctura, Apple Tree, Merck, BMS, Eisai, Debipharm, Incyte, Pfizer, Novartis, MSD. Speaker fee: Pierre Fabre, BMS, Ipsen, Roche, EUSA Pharma, Novartis, Aptitude, AstraZeneca, GSK, Eisai, Calithera, Ultimovacs, Seagen, Merck, eCancer, Inselgruppe, Pfizer, Goldman Sachs, MSD, Regional British Society of Gastroenterology, and Agence Unik); institutional research support (BMS, MSD, Novartis, Pfizer, Achilles Therapeutics, Roche, Nektar Therapeutics, Covance, Immunocore, Pharmacyclics, and Aveo); and grants (Achilles, BMS, MSD, Nektar, Novartis, Pfizer, Roche, Immunocore, Aveo, and Pharmacyclics). A.J.S.F. declares the following: speakers bureau and educational events (BMS, Eisai, Ipsen, Merck, and Pfizer); support for attending meetings and/or travel (Achilles Therapeutics, Adaptimmune, ESMO, Iovance Biotherapeutics. Advisory Boards: Achilles Therapeutics, GSK, Immunocore, and Neogene); and patents planned, issued, or pending: WO2019008375A1 (co-inventor of methods of identifying responders to cancer treatment). (Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu